Atrium Therapeutics, Inc.
Financials
Valuation Metrics
Atrium Therapeutics, Inc.'s Market Cap is $131M. Ranked #3048 of 3,119 in US market (top 98%), #1408 of 1,468 on NASDAQ (top 96%), #258 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 97%) by Market Cap.
Investment Metrics(as of 2026-10-16)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $131M | US#3,048/3,119 Sec#258/265 |
| Revenue | $23M | US#2,784/3,119 Sec#160/265 |
| Net Income | $-93M | US—/3,119 Sec—/265 |
| Total Assets | $281M | US#2,923/3,119 Sec#216/265 |
| Net Assets | $215M | US#2,655/3,119 Sec#189/265 |
| Employees | 511 | US#2,262/3,119 Sec#81/265 |
| Value | ||
| P/B | 0.61x | US#142/3,119 Sec#5/265 |
| P/S | 5.58x | US#2,399/3,119 Sec#88/265 |
| Profitability | ||
| ROE | -43.42% | US#2,644/3,119 Sec#144/265 |
| ROA | -33.22% | US#2,901/3,119 Sec#167/265 |
| Op. Margin | -410.23% | US#2,775/3,119 Sec#149/265 |
| Financial Health | ||
| Debt Ratio | 30.73% | US#349/3,119 Sec#108/265 |
| Total Debt | $2M | US#2,960/3,119 Sec#236/265 |
| Cash | $73M | US#2,404/3,119 Sec#200/265 |
| Current Ratio | 8.73x | US#296/3,119 Sec#89/265 |
| Performance | ||
| 1M Return | -19.26% | US#2,924/3,119 Sec#216/265 |
| From 52W High | -54.26% | US#2,734/3,119 Sec#206/265 |
| 1Y MDD | -53.63% | US#2,543/3,119 Sec#181/265 |
| Trading | ||
| Volume | 190,879 shares | US#2,840/3,119 Sec#259/265 |
| Trading Value | $1M | US#3,019/3,119 Sec#257/265 |
| Per Share | ||
| EPS | $-5.45 | US—/3,119 Sec—/265 |
| BPS | $12.54 | US#1,668/3,119 Sec#56/265 |
Company Info
Atrium Therapeutics, Inc. is a biopharmaceutical company dedicated to revolutionizing the treatment of cardiomyopathies by delivering innovative ribonucleic acid (RNA) therapeutics directly to the heart. Their development-stage portfolio currently includes ATR 1072, a siRNA-based therapy targeting the PRKAG2 gene for the treatment of PRKAG2 syndrome, and ATR 1086, another siRNA therapy aimed at the PLN gene to address PLN cardiomyopathy. The company is also actively developing a wider range of pipeline candidates designed to combat various genetic and cardiac diseases. Founded in 2025, Atrium Therapeutics is based in San Diego, California.